CSIMarket
 
Supernus Pharmaceuticals inc   (SUPN)
 

The Major Pharmaceutical Preparations company declared a superb advance, in the October to December 31 2022 time-frame

company delivered operating surplus of $46.124 million


Published Mar 13 2023
CSIMarket Team / CSIMarket.com


Dryvax_pd company announced EPS of $1.04 and Revenue of $579.78 million in the most recent fiscal period, SUPNs' EPS plummeted $1.04 per share, versus $2.05 eps, earned in the same time-frame a year before, although SUPN saw its Revenue rise by 63.18 % in the same period.

Opposing to the revenue improved by 15.086 % from $579.78 million and income improved by 6.12 % from $0.98 per share.


Net income of $60.711 million in the most recent fiscal period fell by -45.3 % from $110.993 million in the corresponding period a year before. Supernus Pharmaceuticals Inc shifted it's focus on improving sales in the most recent fiscal period, as a result net margin eased to 9.1%.
Operating earnings, fell -68.07% to $46.124 million, squeezing Supernus Pharmaceuticals Inc 's operating margin to 6.91%, from 35.33% in the.

Supernus Pharmaceuticals Inc is expected to report next financial recent numbers on May 11, 2023.



Supernus Pharmaceuticals Inc's Asset Turnover

Supernus Pharmaceuticals Inc's Dividend Growth



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com